Abstract

While transplantation remains the only potentially useful treatment for end-stage organ failure, its widespread use is limited by donor organ failure due to immunological rejection. At present, the success of clinical organ transplantation is dependent on long-term use of non-specific immunosuppressive agents that cause significant morbidity and mortality. Despite recent improvements in graft survival due to the use of potent immunosuppressive drugs like cyclosporine and FK 506, graft rejection continues to occur...

Keywords: acquired thymic tolerance, Alloantigens, Islets